Member Info for Bermudashorts

Chelsea,

Good to hear that you're getting out and about.

Konar was talking about the European patent when he mentioned the passing of 9 months with no objections and that patent is fully granted. The US situation is slightly different. The US patent application covering Moditope peptides was granted way back but there are at least 2 divisional applications still battling their way through the examination process. It could be a while yet.

BioNTech splashing the cash to acquire Kite's TCR platform and manufacturing facility. BioNTech's purchasing power transformed by BNT162b2 of course.

https://www.globenewswire.com/news-release/2021/07/19/2264779/0/en/BioNTech-to-Acquire-Kite-s-Neoantigen-TCR-Cell-Therapy-R-D-Platform-and-Manufacturing-Facility-in-Gaithersburg-MD.html

Ruck,

As I understand it, ImmunID has closed down - their IP was taken over by Adaptive Biotechnologies.

WTP - thanks for the link and good to see Scancell starting to build the infrastructure that has been sorely lacking in the past. For too long now, Lindy Durrant and her team have created these exciting products, so full of potential and then they get stuck in a logjam when it comes to the next stage of development resulting in it taking far too long to take products into scaled back trials. There is clearly now a strategy in place to deal with those issues and for the first time in its history, Scancell has the funds to do justice to Lindy Durrant's innovation.

Crumbs/Konar

Nearly there but the US divisional patent is still being processed and another divisional application was lodged with the US Patent Office in Dec 2020 and published on 1st July. I'm not sure whether it's instead of or in addition to the existing divisional.

Worth noting that when filing the latest divisional application, Scancell also submitted a Track One request . Track One is the US Patent Office's accelerated examination program - a fast track examination scheme. May be wrong but I think this is the first time Scancell have applied for priority examination for any of its patent applications.

https://patentscope.wipo.int/search/en/detail.jsf?docId=US328942288&tab=NATIONALBIBLIO&_cid=P22-KR4T8M-09901-1

Dracula,

You're absolutely correct - big pharma with approved vaccines have already developed and will continue to develop new booster jabs to combat Covid variants. I believe Pfizer and Moderna are already pushing to get these boosters into the arms of people just a few months after receiving their original jabs.

It actually highlights the whole point of Covidity - ie. avoidance of the need (and massive cost) of booster jabs every few months.

roses,

Yep at the moment Zakari is just sitting there as a shell company and I understand that David completely accepts assurances from both Scancell and their nomad that there is no regulatory requirement for an RNS at this stage.

Roses,

Roses - David Evans has/had many more than 1.5m but agree with your 13.37.

AB124/LL - Correct, DE has said he will dispose of his holdings in an orderly manner and that's exactly what he will do, or perhaps has already done.

A new patent application from Redx was lodged with the UK Patent Office on 28th May and appeared in today's journal. The title is giving nothing away 'Compounds'. Will be interesting to find out more when it's published.

https://www.ipo.gov.uk/p-pj?startYear=2021&startMonth=June&startDay=2nd+-+6889&endYear=2021&endMonth=July&endDay=14th+-+6895&filter=4d+pharma&perPage=10&sort=Publication+Date

Crumbs.

If you check Companies House, you'll see Scancell submitted a CH01 form to correct Cliff Holloway's country of residence. Unfortunately, they changed the record for Scancell Holdings from the UK to England instead of Zakari !

Bill,

Once the trial finally gets up and running, recruitment should be relatively quick. I assume the setting for the trial will be those with advanced tumours who have failed other treatments and I don't think there will be any HLA type restrictions as with SCIB1. So far less restrictive than the SCIB1 combo trial and because it will be an open label trial in patients with tumour in situ, initial results should be available quite quickly.

It would be really good now to at least have confirmation from Scancell that all manufacturing issues have been solved and manufacturing is complete.

lol, spot on

Ray,

I guess it goes back to the old taking the brakes off and pressing the accelerator analogy - in these patients simply taking the brakes off with PD-1 monotherapy isn't enough so add in Tavo to drive T cells to the tumour to press the accelerator.

Having said that, given the choice of a therapy delivered via electroporation directly into the tumour or a shot in the arm, I know which I'd choose and I know which one healthcare providers and US insurers would choose given equal efficacy.

Ray,

You can't really compare response rates between the Scancell and OncoSec trials as you're not comparing like for like. The setting for the OncoSec trial is in patients who have previously been treated with PD-1 inhibitors but who have progressed - ie. they are already proven non-responders to PD-1. The Scancell trial will be carried out in patients who are receiving PD-1 therapy as a first line treatment for advanced melanoma, ie. they've not received any prior treatment whatsoever and a proportion of those patients would be expected to respond to the PD-1 as a monotherapy anyway. There's a big difference.

We have discussed OncoSec v Scancell many times in the dim and distant past and Bill's link (thanks) reminded me of this article from 2013 - interesting to read again 7 or 8 years on:-

'I include three companies here not because I think all three of them will succeed (two I believe will)'

https://www.investing.com/analysis/scancell-and-oncosec-looking-good-with-melanoma-immunotherapies-179655

Napolean thanks for posting.

Ivy,

Thanks for the link. This pandemic has certainly brought a new appreciation for the UK's life sciences industry and it's long overdue. As has been shown over the last year or two, the UK really does have some of the best scientists, best institutions and generates some of the best innovation in the World. So often early stage bios are forced to sell IP too early and too cheaply and it nearly always goes overseas - time to properly support the sector and create an environment that allows innovation to flourish and remain in the UK. With that in mind, this line from your link was good to read:-

' can commercialise breakthrough products right here in the UK - rather than elsewhere '

Falsedawn

Good to hear from you.

Add Lucinda and Shri9 (or similar)

Burble's posts have always been excellent and again today he has explained why Scancell's tech. is unique, exciting and highlighted the huge potential. All things Inanaco has also been saying for years .

Burble made a comment at the end of one of his posts that understanding the science helps with understanding the risks. However, he did not say that he agrees with Inanaco's mantra that understanding the science = no risk/less risk (as has been claimed elsewhere). This is important because I'm sure many readers will be influenced by Burble's obvious knowledge, experience, qualifications and calm balanced approach.

IMO AB124 made some valid points on this subject and I wonder why we are happy for some posters to claim that Scancell don't have the expertise to run a phase I trial or don't really have any labs but want to shut down AB124? Odd.

Konar,

Not sure whether that means any changes were made. I have a screenshot taken a few weeks ago and wording looks identical to me..

Following a conversation on advfn, it might be worth adding that there are needle-free electroporation devices.